Evidence map›Paper›PMID 35505469›Full record

SynthesisJournal of medical virology2022

Pulse versus nonpulse steroid regimens in patients with coronavirus disease 2019: A systematic review and meta-analysis.

Waleed Khokher, Azizullah Beran, Saffa Iftikhar, Saif-Eddin Malhas, Omar Srour, Mohammed Mhanna, Sapan Bhuta, Dipen Patel, Nithin Kesireddy, Cameron Burmeister and 3 more

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Steroid treatment for COVID-19: Suitable dose and patients.Lung India : official organ of Indian Chest Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Waleed KhokherDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Azizullah BeranDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.ORCID 0000-0002-4161-942X
Saffa IftikharDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Saif-Eddin MalhasDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Omar SrourDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Mohammed MhannaDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Sapan BhutaDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Dipen PatelDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Nithin KesireddyDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Cameron BurmeisterDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Elizabeth BorchersDepartment of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Ragheb AssalyDepartment of Internal Medicine, University of Toledo, Toledo, Ohio, USA.
Fadi SafiDepartment of Pulmonary and Critical Care Medicine, University of Toledo, Toledo, Ohio, USA.
University of Toledo · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic steroids are associated with reduced mortality in hypoxic patients with coronavirus disease 2019 (COVID-19). However, there is no consensus on the doses of steroid therapy in these patients. Several studies showed that pulse dose steroids (PDS) could reduce the progression of COVID-19 pneumonia. However, data regarding the role of PDS in COVID-19 is still unclear. Therefore, we performed this meta-analysis to evaluate the role of PDS in COVID-19 patients compared to nonpulse steroids (NPDS). Comprehensive literature search of PubMed, Embase, Cochrane Library, and Web of Science databases from inception through February 10, 2022 was performed for all published studies comparing PDS to NPDS therapy to manage hypoxic patients with COVID-19. Primary outcome was mortality. Secondary outcomes were the need for endotracheal intubation, hospital length of stay (LOS), and adverse events in the form of superimposed infections. A total of 10 observational studies involving 3065 patients (1289 patients received PDS and 1776 received NPDS) were included. The mortality rate was similar between PDS and NPDS groups (risk ratio [RR]: 1.23, 95% confidence interval [CI]: 0.92-1.65, p = 0.16). There were no differences in the need for endotracheal intubation (RR: 0.71, 95%: CI 0.37-1.137, p = 0.31), LOS (mean difference: 1.93 days; 95% CI: -1.46-5.33; p = 0.26), or adverse events (RR: 0.93, 95% CI: 0.56-1.57, p = 0.80) between the two groups. Compared to NPDS, PDS was associated with similar mortality rates, need for endotracheal intubation, LOS, and adverse events. Given the observational nature of the included studies, randomized controlled trials are warranted to validate our findings.

Indexed as

COVID-19 Drug TreatmentHumansLength of StaySteroidsTime FactorsSteroidscorticosteroidsCOVID-19hospital stayintubationmortalitypulse dose steroids

Identifiers

PMID35505469
PMCPMC9347719
OpenAlexW4225415747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.